BESPOKE: Study Design, Efficacy End Points, and Methods

Panelists discuss how the BESPOKE study’s innovative design, carefully selected efficacy end points, and rigorous methodological approach aim to evaluate personalized therapeutic interventions with unprecedented precision.

EP: 1.The Role of ctDNA in CRC

Now Viewing

EP: 2.BESPOKE: Study Design, Efficacy End Points, and Methods

EP: 3.Overview of BESPOKE Patient Characteristics

EP: 4.BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

EP: 5.BESPOKE: ctDNA Clearance During and After ACT

EP: 6.Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy

EP: 7.SWOG 80702: Overview of Study Design, Efficacy End Points, and Patient Characteristics

EP: 8.SWOG 80702: Impressions on the Efficacy Data

EP: 9.Potential Role of Tumor-Informed ctDNA in CRC

EP: 10.Importance of Patient-Centric Approach and Patient Education of ctDNA Testing in CRC and Looking Ahead

EP: 11.The Role of ctDNA Testing in Colorectal Cancer Management: Exploring Its Use Alongside Imaging in Challenging Cases

EP: 12.Research Considerations for ctDNA Testing in Colorectal Cancer

Recent Videos